Examples

Four NSCLC drug targets, ranked from evidence

A small, real run: four non-small cell lung cancer drug targets (ALK, EGFR, KRAS, MET) compared pairwise on 20 criteria by one LLM judge, using only the evidence dossiers collected beforehand. 240 judgements, about a fifth of them abstentions where the dossiers held no usable evidence. The ranking is a Bayesian Bradley-Terry-Davidson posterior with intervals; every judgement, rationale and cited source is open below. Not a clinical recommendation.